keyword
MENU ▼
Read by QxMD icon Read
search

triple positive breast cancer

keyword
https://www.readbyqxmd.com/read/28718331/entinostat-for-the-treatment-of-breast-cancer
#1
Dario Trapani, Angela Esposito, Carmen Criscitiello, Luca Mazzarella, Marzia Locatelli, Ida Minchella, Saverio Minucci, Giuseppe Curigliano
Breast cancer accounts for 29% of malignant tumors. It is an heterogenous disease covering a spectrum of different molecular subtypes. Epigenetic aberrations may affect gene expression through DNA and histone proteins modifications thus promoting tumor progression and resistance to anti- tumor treatment. Area covered: This article explores the potential role of entinostat in the treatment of breast cancer. The clinical trials evaluating entinostat are discussed, highlighting preclinical data and early-phase clinical studies results...
July 18, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28717728/prevalence-of-triple-negative-breast-cancer-in-india-systematic-review-and-meta-analysis
#2
REVIEW
Gurprataap S Sandhu, Sebhat Erqou, Heidi Patterson, Aju Mathew
PURPOSE: There is considerable variation in prevalence rates of triple-negative breast cancer (TNBC) reported by various studies from India. We performed a systematic review and literature-based meta-analysis of these studies. METHODS: We searched databases of Medline, Scopus, EMBASE, and Web of Science for studies that reported on the prevalence of TNBC in India that were published between January 1, 1999, and December 31, 2015. We extracted relevant information from each study by using a standardized form...
December 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28715634/a-novel-strategy-utilizing-extracellular-cysteine-rich-domain-of-membrane-receptor-for-constructing-d-peptide-mediated-targeted-drug-delivery-systems-a-case-study-on-fn14
#3
Zhuoxuan Li, Jing Xie, Shan Peng, Sha Liu, Ying Wang, Weiyue Lu, Jie Shen, Chong Li
The development of proteolysis-resistant D-peptide ligands for targeted drug/gene delivery has been greatly limited, due to the challenge lies in the chemical synthesis of membrane receptors without altering their structures. In the present research, a novel strategy utilizing self-stabilized extracellular cysteine-rich domain (CRD) of membrane receptor was developed to construct D-peptide ligands and their mediated targeted drug delivery systems. Fibroblast growth factor-inducible 14 (Fn14), a cell surface receptor overexpressed in many cancers including pancreatic and triple-negative breast cancers, was selected as the model receptor...
July 17, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/28709150/mammography-and-ultrasound-effective-features-in-differentiating-basal-like-and-normal-like-subtypes-of-triple-negative-breast-cancer
#4
Zeng Zeng, Chun Jie Hou, Qiao Hong Hu, Ying Liu, Ceng Wang, Ran Wei, Xiao Ming Fan
The aim of our study was to find effective features of mammography and ultrasound in differentiating Basal-like breast cancer (BBC) and Normal-like breast cancer (NBC), two subtypes of triple negative breast cancer (TNBC). From January 2014 to March 2017, we retrospectively reviewed 91 patients who were pathologically confirmed as TNBC. According to immunohistochemical cytokeratin 5/6 (CK5/6) and Epidermal Growth Factor Receptor (EGFR), TNBCs were classified into BBCs group and NBCs group. Both CK5/6 and EGFR were negative defined to be NBC, whereas if any of CK5/6 or EGFR was positive then defined as BBC...
July 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28707744/the-impact-of-molecular-subtype-on-breast-cancer-recurrence-in-young-women-treated-with-contemporary-adjuvant-therapy
#5
Hanan Alabdulkareem, Tiffany Pinchinat, Sarah Khan, Alyssa Landers, Paul Christos, Rache Simmons, Tracy-Ann Moo
Breast cancer is the leading cause of cancer death in women younger than 40 years. Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive subtypes have a particularly poor prognosis in this age group. The purpose of this study was to compare rates of recurrence among breast cancer subtypes in young patients treated with modern adjuvant systemic therapy. A retrospective review of breast cancer patients managed at a major academic breast center between May 2000 and November 2014 was performed...
July 14, 2017: Breast Journal
https://www.readbyqxmd.com/read/28701032/bcl2-regulation-according-to-molecular-subtype-of-breast-cancer-by-analysis-of-the-cancer-genome-atlas-database
#6
Ki-Tae Hwang, Kwangsoo Kim, Ji Hyun Chang, Sohee Oh, Young A Kim, Jong Yoon Lee, Se Hee Jung, In Sil Choi
Purpose: We investigated BCL2 regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database. Materials and Methods: We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data...
July 4, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28699810/a-balanced-level-of-profilin-1-promotes-stemness-and-tumor-initiating-potential-of-breast-cancer-cells
#7
Chang Jiang, Zhijie Ding, Marion Joy, Souvik Chakraborty, Su Hyeong Kim, Ralph Bottcher, John Condeelis, Shivendra Singh, Partha Roy
Profilin-1 (Pfn1) is an important actin-regulatory protein that is downregulated in human breast cancer and when forcibly elevated, it suppresses the tumor-initiating ability of triple-negative breast cancer cells. In this study, we demonstrate that Pfn1 overexpression reduces the stem-like phenotype (a key biological feature associated with higher tumor-initiating potential) of MDA-MB-231 (MDA-231) triple-negative breast cancer cells. Interestingly, the stem-like trait of MDA-231 cells is also attenuated upon depletion of Pfn1...
July 12, 2017: Cell Cycle
https://www.readbyqxmd.com/read/28696856/internal-thoracic-lymphadenopathy-in-breast-cancer
#8
Ashley R Cahoon, Benjamin D Smith, Wei T Yang
The internal thoracic (IT) nodal basin is a first-echelon drainage pathway in the breast, accounting for up to a quarter of its lymphatic drainage, primarily from the deep structures of the breast. The presence of internal thoracic node (ITN) metastases upstages the breast cancer (BC) patient to a minimum of clinical stage III disease. Medial tumors, deep tumors, young age, axillary nodal metastases, tumors of a high nuclear grade, lymphovascular invasion, and triple-negative hormone receptor status are predisposing factors for ITN metastases from primary BC...
July 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28696357/myc-driven-pathways-in-breast-cancer-subtypes
#9
REVIEW
Yassi Fallah, Janetta Brundage, Paul Allegakoen, Ayesha N Shajahan-Haq
The transcription factor MYC (MYC proto-oncogene, bHLH transcription factor) is an essential signaling hub in multiple cellular processes that sustain growth of many types of cancers. MYC regulates expression of RNA, both protein and non-coding, that control central metabolic pathways, cell death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance. Activation of MYC has been widely reported in breast cancer progression. Breast cancer is a complex heterogeneous disease and treatment options are primarily guided by histological and biochemical evaluations of the tumors...
July 11, 2017: Biomolecules
https://www.readbyqxmd.com/read/28693153/clinical-outcome-of-brain-metastases-differs-significantly-among-breast-cancer-subtypes
#10
Nadja E Oehrlich, Loukia M Spineli, Frank Papendorf, Tjoung-Won Park-Simon
Brain metastases in patients with breast cancer are associated with a poor survival rate. A small number of studies have challenged this premise, suggesting that survival times following brain metastasis differ significantly between breast cancer subtypes. In the current study, overall survival (OS), brain metastases-free survival (BMFS) and survival following brain metastases (SFBM) were found to be associated with the intrinsic breast cancer subtype. A total of 1,147 patients with invasive breast cancer who were treated at the Hannover Medical School between January 2004 and December 2010 were included, from which 54 patients with brain metastases were identified...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28692382/use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-early-stage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-focused-update
#11
Ian Krop, Nofisat Ismaila, Fabrice Andre, Robert C Bast, William Barlow, Deborah E Collyar, M Elizabeth Hammond, Nicole M Kuderer, Minetta C Liu, Robert G Mennel, Catherine Van Poznak, Antonio C Wolff, Vered Stearns
Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on the use of adjuvant systemic therapy. Methods ASCO uses a signals approach to facilitate guideline updates. For this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy) study to evaluate the MammaPrint assay in 6,693 women with early-stage breast cancer provided a signal. An expert panel reviewed the results of the MINDACT study along with other published literature on the MammaPrint assay to assess for evidence of clinical utility...
July 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28690656/imaging-surveillance-for-survivors-of-breast-cancer-correlation-between-cancer-characteristics-and-method-of-detection
#12
A Jung Chu, Jung Min Chang, Nariya Cho, Woo Kyung Moon
PURPOSE: The aim of our study was to investigate the characteristics of primary and recurrent breast cancers and the correlation between cancer subtypes and detection modes. METHODS: Between 2003 and 2013, 147 cases of recurrent breast cancer in 137 women (mean age, 45.30±10.78 years) were identified via an annual clinical examination using radiological studies among 6,169 patients with a breast cancer history (mean follow-up period, 13.26±1.78 years). Clinical, radiological, and pathological findings including immunohistochemistry findings of primary and recurrent cancers were reviewed...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690651/mutations-of-the-epidermal-growth-factor-receptor-gene-in-triple-negative-breast-cancer
#13
Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae
PURPOSE: Epidermal growth factor receptor (EGFR) is considered a potential therapeutic target for anti-EGFR therapy in triple-negative breast cancer (TNBC). However, the frequency of EGFR gene mutation in TNBC is low and varies with ethnicity. This study aimed to investigate the incidence of EGFR gene mutation in TNBC. METHODS: EGFR protein expression was evaluated by immunohistochemistry in tissue microarrays of 493 TNBC cases using four different primary antibodies, which included mutation-specific antibodies...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690648/recent-advances-in-the-neoadjuvant-treatment-of-breast-cancer
#14
REVIEW
Gábor Rubovszky, Zsolt Horváth
In the last few decades, neoadjuvant therapy for breast cancer has gained considerable therapeutic importance. Despite extensive clinical investigations, it has not yet been clarified whether neoadjuvant therapy would result in improved survival in comparison with the standard adjuvant setting in any subgroups of patients with breast cancer. Chemotherapy is especially effective in the treatment of endocrine insensitive tumors, and such ther-apeutic benefit can be assumed for patients with triple-negative, or hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancer...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690105/de-escalating-and-escalating-systemic-therapy-in-triple-negative-breast-cancer
#15
Lisa A Carey
Triple negative breast cancer has the highest relapse risk of all the clinical subsets, although the escalation of chemotherapy has benefited this subset substantially over recent years. Systemic options are limited to chemotherapy, which makes meaningful de-escalation or escalation of therapy more challenging but possible. Observational cohorts suggest a less than 10% risk of relapse and minimal if any benefit of chemotherapy in very small (<1 cm), node-negative triple negative disease. In higher risk, particularly node-positive disease, anthracycline/taxane-based regimens remain standard...
July 7, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28679772/prognostic-impact-of-circulating-tumor-cells-for-breast-cancer-patients-treated-in-the-neoadjuvant-geparquattro-trial
#16
Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, Jorn Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gunter von Minckwitz, Michael Untch, Klaus Pantel
This study aimed to evaluate the prognostic impact of circulating tumor cells (CTCs) detected in patients with operable or locally advanced breast cancer before and after neoadjuvant therapy (NT) within the clinical trial GeparQuattro.<br />Experimental Design: Data on CTCs enumerated with the CellSearch™ system were available for 213 and 207 patients before and after NT, respectively. Associations of CTCs with disease-free (DFS) and overall survival (OS) were analyzed by non-parametric Kaplan-Meier estimates and parametric Cox regression...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28673538/tailoring-radiotherapy-according-to-cancer-subtypes
#17
Roberto Orecchia
Radiotherapy is able to improve locoregional control in breast cancer patients both after breast conserving surgery or mastectomy, with positive impact in high-risk patients for long-term survival. Recent advances in the precision of radiotherapy were based on the choice of the appropriate fractionation and technique. But the concept of adaptive radiotherapy is not only technical, and includes the biologic characterisation of the breast tumor. The knowledge that different subtypes of breast cancer can have distinct locoregional patterns of recurrence is consisted in the literature data...
June 30, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28671018/gper-1-gpr30-a-novel-estrogen-receptor-sited-in-the-cell-membrane-therapeutic-coupling-to-breast-cancer
#18
Luis Molina, Carlos D Figueroa, Kanti D Bhoola, Pamela Ehrenfeld
Breast cancer is clinically classified as 'estrogen-positive' when at least 1% of cancer cells stain for the estrogen receptor alpha (ERα). However, recent research on both basic and clinical aspects of breast cancer suggests that GPER-1 (G protein-coupled estrogen receptor-1) may have an important role in breast cancer. Areas covered: This review provides a comprehensive and systematic literature search on GPER-1. We have focused on the role of GPER-1 in breast cancer and on resistance to endocrine therapy, an unsolved clinical issue still under discussion...
July 12, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28670879/molecular-subtypes-of-breast-cancers-from-myanmar-women-a-study-of-91-cases-at-two-pathology-centers
#19
Thar Htet San, Masayoshi Fujisawa, Soichiro Fushimi, Lamin Soe, Ngu Wah Min, Teizo Yoshimura, Toshiaki Ohara, Myint Myint Yee, Shinsuke Oda, Akihiro Matsukawa
Background: Breast cancer is the most common cancer in Myanmar women. Revealing the hormonal receptor status, human epidermal growth factor receptor 2 (HER2) and Ki-67 expression is useful for estimating patient prognosis as well as determination of treatment strategy. However, immunohistochemical features and classification of molecular subtypes in breast cancers from Myanmar remain unknown. Methods: The clinicopathological features of 91 breast cancers from Myanmar women were examined. Immunohistochemistry was performed on tissue specimens with antibodies to estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki-67, cytokeratin (CK)5/6 and CK14...
June 25, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28670138/sr-b1-targeted-nanodelivery-of-anti-cancer-agents-a-promising-new-approach-to-treat-triple-negative-breast-cancer
#20
Rebecca Johnson, Nirupama Sabnis, Xiangle Sun, Ruhani Ahluwalia, Andras G Lacko
Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs...
2017: Breast Cancer: Targets and Therapy
keyword
keyword
117994
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"